Biological sex is binary and immutable in humans; the claim that subjective identity overrides it, and that medicalization is the indicated response, rests on weak evidence and produces measurable harms.
Sex in mammals is defined by the type of gamete an organism’s reproductive system is organized to produce: small (sperm) or large (ova). There is no third gamete, and disorders of sexual development are developmental variations within that binary, not evidence of a spectrum or a “sex assigned at birth.” Chromosomes, gonads, and secondary sex characteristics are downstream of that organization. No hormonal or surgical intervention changes gamete type, skeletal morphology set during puberty, or the sex-specific organization of the brain that is already largely complete before birth. Calling this a spectrum is a redefinition of terms, not a biological discovery.
Gender dysphoria is a real and often distressing condition. It is not, by itself, evidence that someone is a member of the opposite sex. Twin studies and desistance data show it is not a fixed innate identity in the way the ideological claim requires. Classic studies of boys with childhood-onset dysphoria (Steensma et al., Singh et al.) found that the large majority desisted by adulthood when not socially or medically transitioned; many later identified as gay or lesbian. The post-2010 shift—predominantly adolescent females with no childhood history, high rates of autism, anxiety, depression, trauma, and same-sex attraction, clustered in friend groups—is the pattern expected of social contagion, not of a suddenly discovered biological subtype. Littman’s rapid-onset work and the Cass Review’s documentation of the change in sex ratio and comorbidity profile describe that pattern.
The affirmative medical pathway lacks the evidence base required for irreversible interventions. The Cass Review (NHS England, 2024) concluded that the evidence for puberty blockers is weak, that they do not clearly improve body satisfaction or mental health, and that most youth who start them proceed to cross-sex hormones. Systematic reviews in Sweden, Finland, Norway, and the UK have led those countries to restrict blockers and hormones for minors to trials or exceptional cases. Long-term data do not show that transition reduces suicide to population levels. The Swedish cohort study (Dhejne et al., 2011) found post-surgical transsexuals had suicide rates many times higher than matched controls; later registry work from Sweden and Denmark continues to show substantially elevated psychiatric morbidity and suicide attempts after transition. That is not proof that transition causes the residual risk, but it falsifies the claim that medicalization reliably resolves it.
Harms are concrete. Cross-sex hormones produce sterility when preceded by blockers, sexual dysfunction, and (for females) elevated cardiovascular and metabolic risk; mastectomy and genital surgery remove healthy tissue and create lifelong surgical patients. Male-pattern advantage in strength, speed, and skeletal leverage is not erased by testosterone suppression after male puberty, which is why most sporting bodies have reinstated sex-based categories. Single-sex spaces exist because of average differences in aggression and sexual offending, not because of identity. Redefining them by self-identification predictably produces conflicts that data from prisons and shelters have already recorded.
The ideological package goes beyond clinical caution. It treats dissent as bigotry, substitutes “affirmation” for differential diagnosis, and has been adopted by institutions faster than the evidence. European health authorities that reviewed the same literature have moved in the opposite direction from U.S. activist guidelines. That divergence is the empirical argument: when systems prioritize systematic evidence over identity claims, they restrict the interventions.
can you try to come up with an actual argument other than spamming images